Apceth Gmbh & Co Kg

Other

Leland Stanford Junior University

Applied Research Systems Ars Holding N.v.

Peter Nelson

Ralf Huss

Amanda Proudfoot

Alan M Krensky

Manfred J Stangl

Timothy N C Wells

Benjamin D Ortiz

Matthias C Raggi

Hermann-Joseph Grone

Manfred Stangl

Matthias Raggi

This invention provides a method for treating a subject afflicted with a tumor using genetically modified mesenchymal stem cells, wherein each genetically modified mesenchymal stem cell contains an exogenous nucleic acid comprising (i) a cytotoxic protein-encoding region operably linked to (ii) a promoter or promoter/enhancer combination, whereby the cytotoxic protein is selectively expressed when the genetically modified mesenchymal stem cells come into proximity with the tumor's stromal tissue. This invention further provides genetically modified mesenchymal stem cells for use in this method.

Genetically modified mesenchymal stem cell that express an exogenous cytotoxic protein

The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of tumor cells and render tumor cells sensitive to FAS-induced apoptosis. Furthermore, the fusion constructs of the present invention are effective agents useful in wound healing applications. In one embodiment, the TIMP is linked to mucin followed by GPI in order to enhance surface presentation. The use of GPI to link TIMP renders the resulting fusion protein particularly useful as an anti-cancer agent for the treatment of cancer, and, in particular, any residual cancer following an incomplete surgical resection of primary tumors in an individual.

Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI)-anchors for treatment of cancer and skin lesions

This invention provides novel stem cell-based methods for treating a number of conditions. These methods employ CD34stem cells, and have a tremendous advantage in that they do not require myeloablation in the subject being treated. The CD34stem cells used in the instant methods can be genetically modified or not, depending on the disorder treated.

CD34 stem cell-related methods and compositions

The use of a chemokine receptor antagonist together with a cyclosporin to produce a pharmaceutical composition for treating or preventing rejection of transplanted organs, tissues or cells is herein disclosed. Said pharmaceutical compositions for the simultaneous, sepatate or sequential use of its active ingredients for the above specified therapy are also disclosed and claimed. In particular, the use of Met-RANTES together with cyclosporin A to produce a pharmaceutical composition for the treatment of renal allograft transplant rejection is experimentally shown.

Chemokine receptor antagonist and cyclosporin in combined therapy

The present invention provides elements derived from a human RANTES promoter that induce expression of a heterologous coding sequence. The invention further provides expression vectors comprising the elements, and host cells comprising the expression vectors. The invention further provides methods of inducing the expression of a heterologous protein in a host.

Enhancer sequences for late T cell expressed genes

Growing community of inventors

Munich, Germany

Peter Nelson